Diabetestherapie bei chronischer Niereninsuffizienz

Schlüsselwörter

diabetische Nephropathie - Diabetestherapie - Hypoglykämie - Insulinresistenz

Keywords

diabetic nephropathy - diabetes treatment - hypoglycemia - insulin resistance

• Literatur

• 1 Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232
• 2 Aronoff GR, Berns JS, Brier ME et al. Drug prescribing in renal failure: Dosing guidelines for adults. 4th. ed, Philadelphia: American College of Clinicians; 1999
• 3 Barkoudah E, Skali H, Uno H et al. Mortality Rates in Trials of Subjects With Type 2 Diabetes. J Am Heart Assoc 2012; 1: 8-15
• 4 Biesenbach G, Raml A, Schmekal B et al. Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients. Diabet Med 2003; 20: 642-645
• 5 Budnitz DS, Lovegrove MC, Shehab N et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365: 2002-2012
• 6 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter. 1. Auflage. 2010. Available from: http://www.diabetes.versorgungsleitlinien.de
• 7 Chatzikyrkou C, Haller H, Menne J. Albuminurie. Prognostischer Marker oder therapeutisches Ziel?. Internist 2012; 53: 38-44
• 8 Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 2010; 33: 562-568
• 9 de Boer IH, Rue TC, Hall YN et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011; 305: 2532-2539
• 10 Deb DK, Sun T, Wong KE et al. Combined vit­amin D analog and AT1 receptor antagonist syn­ergistically block the development of kidney di­sease in a model of type 2 diabetes. Kidney Int 2010; 77: 1000-1009
• 11 Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 2000; 108 (Suppl. 02) 234-242
• 12 Frei U, Schober-Halstenberg H-J. Nierenersatztherapie in Deutschland. Bericht 2006/2007. http://www.bundesverband-niere.de/files/QuaSi-Niere-Bericht_2006-2007.pdf
• 13 Holstein A, Stumvoll M. Contraindications can damage your health-is metformin a case in point?. Diabetologia 2005; 48: 2454-2459
• 14 Hyppönen E, Läärä E, Reunanen A et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358: 1500-1503
• 15 Johnston SS, Conner C, Aagren M et al. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 2011; 34: 1164-1170
• 16 Jonsson A, Rydberg T, Sterner G et al. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 1998; 53: 429-435
• 17 Kobayashi S, Maejima S, Ikeda T et al. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2000; 15: 65-70
• 18 Krolewski AS. Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int 1999; 55: 1582-1596
• 19 Lambers Heerspink HJ, Brantsma AH, de Zeeuw D et al. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 2008; 168: 897-905
• 20 Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
• 21 List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657
• 22 Mak RHK. Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney International 1998; 54: 603-607
• 23 Marshall SM. Diabetic nephropathy in type 1 diabetes: has the outlook improved since the 1980s?. Diabetologia 2012; 55: 2301-2306
• 24 Masoudi FA, Inzucchi SE, Wang Y et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111: 583-590
• 25 Merker IF, Gallwitz B, Waldeck B et al. Prevalence of chronic kidney disease in type 2 diabetes – results from a nationwide survey in Germany. Diabetologia 2012; 55 (Suppl. 01) S 160
• 26 Meyer C, Stumvoll M, Nadkarni V et al. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 1998; 102: 619-624
• 27 Moen MF, Zhan M, Hsu VD et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1121-1127
• 28 Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203
• 29 Oomichi T, Emoto M, Tabata T et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29: 1496-1500
• 30 Rave K, Heise T, Pfützner A et al. Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 2001; 24: 886-890
• 31 Rosenkranz B, Profozic V, Metelko Z et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996; 39: 1617-1624
• 32 Roussel R, Travert F, Pasquet B et al. Reduction of atherothrombosis for continued health (REACH) registry investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010; 170: 1892-1899
• 33 Salpeter SR, Greyber E, Pasternak GA et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; CD002967
• 34 Schumacher S, Abbasi I, Weise D et al. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 2001; 57: 147-152
• 35 Selvin E, Bolen S, Yeh HC et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 2070-2080
• 36 Shurraw S, Hemmelgarn B, Lin M et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011; 171: 1920-1927
• 37 The United States Renal Data System: 2006 annual DATA report. Am J Kidney Dis 2006; 49: 137-138
• 38 Thorand B, Zierer A, Huth C et al. Effect of serum 25-hydroxyvitamin D on risk for type 2 diabetes may be partially mediated by subclinical inflammation: results from the MONICA/KORA Augsburg study. Diabetes Care 2011; 34: 2320-2322
• 39 Weber D, von Hübbenet J, Heckermann S et al. Morbiditätsprofile von Diabetespatienten. Diabetes, Stoffwechsel & Herz 2011; 20: 7-14
• 40 Levey AS, de Jong P, Coresh J et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80: 17-28